← Patent-cliff monitor small molecule RINVOQ UPADACITINIB
Loss of exclusivity March 2038 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name RINVOQ Active ingredient UPADACITINIB Strength 30MG Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval January 2022 Marketing status RX
Listed patents Patent Expires Type 11607411 March 2038 use U-3341 11564922 March 2038 use U-3624 11186584 October 2036 substance 12110298 October 2036 substance, product 10550126 October 2036 use U-3298 11535626 October 2036 use U-3298 11767326 October 2036 use U-3298 12091415 October 2036 product 10981924 October 2036 product 10981923 October 2036 substance 11718627 October 2036 substance, product 10344036 October 2036 product 11680069 October 2036 substance, product 11773105 October 2036 substance, product 9951080 October 2036 substance, product 11661425 October 2036 substance, product 12116373 October 2036 product 10730883 October 2036 product 12077545 October 2036 product 11198697 October 2036 product RE47221 August 2033 substance 8962629 January 2031 substance
Regulatory exclusivity Code Expires ODE-481 April 2031 I-946 April 2027 NPP April 2027 I-919 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.